CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology

Contributed by: Business Wire

Logo

Tags

Research

Technology

Hospitals

FDA

Other Technology

Clinical Trials

Health Technology

Cardiology

Health

Science

More Like This

CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients

Chris O'Connell, Chairman, Board of Directors, CorFlow

CorFlow Therapeutics Appoints Chris O'Connell as Chairman of the Board of Directors

Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt

PR Newswire associated0

PulseCath Achieves MDR CE Certification for iVAC 2L, Paving the Way for Complex High-Risk Percutaneous Coronary Interventions

PR Newswire associated0

Heart Failure start-up, Acorai, secures €2.3m grant funding from the European Commission

PR Newswire associated0

CONCEPT MEDICAL RECEIVES US FDA IDE APPROVAL FOR MAGICTOUCH AVF INDICATION, THEIR FIFTH US CLINICAL STUDY APPROVAL FOR THE MAGICTOUCH PORTFOLIO

VISABL-AFL Procedure at ICPS (Photo: Business Wire)

Imricor’s VISABL-AFL Trial for US FDA Approval Commences at Cardiovascular Institute of South Paris

Corvia's RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data